UNLEASH THE POWER OF RNAa TECHNOLOGY TO TURN ON NEARLY ANY BENEFICIAL GENE

Ractigen is an early-stage biopharmaceutical company founded on a next-generation approach to RNAa committed to bringing to market first-in-class therapeutics with a focus on cancer and debilitating genetic diseases. Ractigen is developing a rich pipeline of candidate therapeutics and actively advancing our lead compound through IND-enabling development. We implement a series of structural and chemical modifications developed internally that greatly improve the pharmacological properties of candidate drugs and maximize target gene output.